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February´10 to September´15. To be included in the study, 
the treatment had to fulfill the criteria: (1) include a 
previous treatment of at least 45Gy of EBRT to the pelvis 
concomitant with cisplatin; (2) the BT boost consisted in 
insertion of interstitial Utrecht applicator under spinal 
anesthesia and individualized MRI planning. Each treatment 
was composed of 2 applications (7 days apart), with 2 
separated fractions (in 24 hours) of nominal 7 Gy (the aim is 
to obtain the HR-CTV and IR-CTV D90 higher than 85 and 65 
Gy EQD2 respectively keeping the OAR doses as low as 
possible with limits of D2cc of rectum and sigmoid lower than 
70 Gy EQD2 and 85 Gy EQD2 in case of bladder). Applicator 
withdrawal was performed at the surgical theatre. Toxicity 
score (gynaecological bleeding) were defined by CTCAE v4.0. 
 
Results: 110/122 (90.16%) patients were IIB stage or bigger, 
and in 68% of patients 6 needles were inserted in both 
applications. Median tumour volume at diagnoses was 39.8 cc 
(8.79-205) and median HR-CTV volume at first application 
was 18.01 cc (7.36-116.59). The final median biologically 
equivalent doses (EQD2) were D90 HR-CTV = 89.75 Gy10 
(78.50-94.00) and D90 IR-CTV = 67.90 Gy10 (58.60-77.40).  
For the first application, needles were used in all patients, 
and 4 (3.2%) patients required vaginal tamponade and/or 
stitch (Grade 2 CTCAE v4.0), and 2 (1.6%) patients required 
transfusion and/ or endoscopic intervention (Grade 3 CTCAE 
v4.0).  
For the second application, needles were used in 114 
patients, and 5 (4.3%) patients required vaginal tamponade 
and/or stitch (Grade 2 CTCAE v4.0) without bigger toxicities. 
 
Conclusion: Our results suggest that interstitial IGBT as 
recommended by the GEC-ESTRO, is a safe option without 
life-threatening consequences due to bleeding, and 
dosimetric results compare favorably with the traditional 
technique. 
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Purpose or Objective: MR-guided brachytherapy (MRgBT) 
improves local control and survival in patients with cervical 
cancer. It is expected that MRgBT will be standard of care 
within 5 years. MRgBT is more demanding of resources and 
optimized processes will be of great importance in assuring 
its widespread availability. Our aim was to determine the 
value of imaging and adaptive replanning prior to each MRgBT 
fraction compared to a less resource intensive approach 
tailored to specific technique considerations. 
 
Material and Methods: A total of 20 patients with cervical 
cancer who received external beam radiotherapy (EBRT: 45-
50.4 Gy in 1.8-2 Gy fractions) and high dose rate MRgBT (28 
Gy in 4 fractions using 2 insertions) were included in this 
study. A tandem/ring applicator (TR) was used in 9 patients, 
and a TR with interstitial needles in 4 patients for all 4 
fractions. In 3 of these 4 patients, further plan adaptation 
with increase in number of needles was performed for 
fractions 3 and 4. In the remaining 7 patients, a TR alone was 
used for fractions 1 and 2 and a TR plus needles for fractions 
3 and 4 to improve target coverage or OAR sparing. All 
patients underwent MR imaging, contouring and planning 
prior to each fraction. To simulate a more efficient approach 
with only one plan per insertion, optimized fraction 1 plan 
was applied to fraction 2 anatomy, and optimized fraction 3 
plan was applied to the fraction 4 anatomy. To assess value 
of plan adaptation, projected total dose from first insertion 
was compared to the final total dose following plan 
adaptation. 
 
Results: There was no systematic change in the high-risk 
clinical target volume (HRCTV) across fractions (mean range 
41-44 cm3). Mean cumulative HRCTVD90 with daily plan 
optimization was 92 Gy10, and the mean rectal, sigmoid and 
bladder D2cc doses were 67, 65 and 83 Gy3 respectively. 
There were no clinically significant changes in the mean 
HRCTV or OAR D2cc doses with only two plans prior to 
fractions 1 and 3. The GEC-ESTRO HRCTV target dose >85 
Gy10 was achieved in 16/20 patients with either daily plan 
optimization or planning only twice. All GEC-ESTRO OAR 
target doses (rectum <75 Gy3, sigmoid <75 Gy3, bladder <90 
Gy3) were achieved in 14/20 patients with optimized daily 
replanning, and this was maintained when only two plans 
were used. Plan adaptation with addition of interstitial 
needles for second insertion resulted in improved HRCTVD90 
dosimetry in 6/10 cases and in improved OAR dosimetry in 
4/10 cases. 
 
Conclusion: MRgBT can potentially improve outcomes of 
cervical cancer patients but is more resource intensive. This 
study suggests that improvements in efficiency can be 
achieved through process analysis and optimization. While 
adaptive MR-based replanning is fundamental to achieving 
the benefits of MRgBT, replanning at strategic intervals may 
be as effective as daily replanning with considerable savings 
in resources. 
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Purpose or Objective: To compare dosimetric plans using a 
commercially model based dose calculation algorithm 
(MBDCA) following TG186 recommendations, and the 
conventional TG43 method in an 192Ir high dose rate (HDR) 
gynaecological brachytherapy (BT) procedures using two 
types of cylindrical applicators. 
 
Material and Methods: We analyzed the data of six patients 
with cervical carcinoma, receiving a 192Ir HDR brachytherapy 
treatment. The dose was delivered with a micro-Selectron 
afterloader. A treatment plan was performed using both the 
TG43 and TG186 dose calculation methods of the Oncentra 
Brachy v4.5 treatment planning system (TPS). Two cylindrical 
applicators, of 30 mm and 35 mm diameter were used: the 
Vaginal Applicator Set and the Shielded Cylindrical Applicator 
Set, by Nucletron. The treatment dose is prescribed at 0.5 
cm distance from the cylinder wall (prescription point), with 
a treated extension of 3 cm. Analysis included dose volume 
histograms (DVH) for bladder and rectum and prescription 
point, according to American Brachytherapy Society (ABS) 
consensus guidelines (2012). The TG186 results were 
obtained using the standard accuracy level option of model-
based algorithm (Oncentra Brachy-Advanced Collapsed cone 
Engine (ACE), Elekta), resulting in calculation times on the 
order of 40 s. 
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Figure 1 - Mean (point), maximum (triangle) and minimum 
(square) value and standard deviation (line) of the difference 
between TG43 and TG186 results, for the dose points, 
bladder and rectum. 
 
Results: In all cases, the obtained dose following the TG186 
method was lower than that obtained with the TG43 
recommendations. Moreover, differences were found 
between the two described applicators (that had never been 
noticed with the TG43). The prescribed dose and the dose to 
2cc of the bladder and rectum varied as follows (figure 1): 
between 0.4% and 2.7% for the prescribed dose, between 
0.6% and 2.5% for the bladder and between 0.9% and 2.7% for 
the rectum. 
 
Conclusion: Differences were found between the dosimetry 
plans obtained with the TG43 and our model based dose 
calculation algorithm following TG186 recommendations. A 
deeper knowledge of this new algorithm and its applications 
in a more accurate dose calculation will be the future of this 
work. 
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Purpose or Objective: To assess the loco-regional efficacy 
and toxicity of a multimodal strategy including brachytherapy 
(BT) as part of the adjuvant treatment of localized high-
grade uterine sarcoma. 
 
Material and Methods: A single center retrospective analysis 
of patients (pts) treated from 1985 to 2015 was conducted. 
104 pts with high-grade uterine sarcoma were identified. 80 
pts had leiomyosarcomas, 17 undifferentiated sarcomas, 3 
rhabdomyosarcomas and 1 high grade adenosarcoma. 10 pts 
had a microscopic (n = 8) or macroscopic (n = 2) positive 
surgical margins. 
 
Results: The median follow-up time was 5.4 years. 57 pts 
underwent perioperative chemotherapy. 102 pts underwent 
postoperative external beam radiation therapy (EBRT) 
followed by a BT boost, and 2 pts received BT without EBRT. 
The median pelvic EBRT dose was 45 Gy (range 25-50.4). 69 
pts were treated with HDR BT (median dose = 10Gy), 33 with 
LDR (median dose = 15Gy), and 2 with PDR without EBRT 
(median dose = 60Gy). The 5-year local-regional failure-free 
survival and overall survival rates were 93% (CI 95% = 87-
99%), and 73%(CI 95% = 0.63-0.84%) respectively. Only 5 
vaginal recurrences were identified. 2 pts presented grade 3 
late toxicity, all other side effects were grade 2 or less. 
 
Conclusion: Adjuvant BT included in a multimodal treatment 
was associated with a high loco-regional control rate and 
acceptable acute and late toxicity in patient with localized 
high-grade uterine sarcoma. 
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Purpose or Objective: This study aims to demonstrate 
effective and non-invasive virtual pre-planning using week 5 
MRI without the need of applicator in-situ for image-guided 
cervix brachytherapy.  
 
Material and Methods: 15 patients with stage IB2-IVA 
cervical cancers were treated at our institution in January to 
October 2015 using chemoradiation and brachytherapy. All 
patients received whole pelvic radiotherapy 45Gy in 25 
fractions over 5 weeks, with concurrent weekly cisplatin 
40mg/m2 for up to 6 cycles, followed by additional 
parametrial boosting 10-16G in 5-8 fractions over 1-2 weeks. 
HDR brachytherapy using Ir-192 was performed in all patients 
at week 6 and 7, using Vienna schedule3 of 2 weekly 
insertions with 2 consecutive fractions per week, and first 
insertion was approximately 4-7 days after completion of 
whole pelvic radiotherapy. Treatment aim was 7Gy to HRCTV 
D90 each for 4 fractions. Week 5 MRI was performed in all 
patients, and HRCTVwk5 was contoured. Virtual preplanning 
was done with proposed applicators according to pre-
brachytherapy clinical assessment of dedicated oncologist. An 
estimated D90 for HRCTV (D90wk5) was then compared with 
the actual D90 HRCTV at week 6 and week 7. Maximum 
diameter for HRCTV at week 6 were measured, and plans 
with suboptimal coverage after brachytherapy was regarded 
as having cumulative D90 HRCTV </= 83.9Gy.  
 
Results: All 15 patients completed chemoradiation with 
schedule indicated. The choice of applicators was dependent 
on geometry of tumor (tandem and ovoids or ring or 
cylinder). Five patients were noted to have suboptimal tumor 
coverage, with cumulative D90 HRCTV dose ranging from 40.7 
to 70.7 Gy. The corresponding maximum diameter of week 6 
HRCTV was found to have significant correlation with 
cumulative HRCTV D90, and a cut-off value of tumor 
diameter 4.63cm could predict cumulative dose of 83.9 Gy. 
Based on the initial results, 2.5cm tumor radius from midline 
was decided to be the cut-off for using interstitial needles to 
improve dosimetry. With the implementation of interstital 
needles in September 2015, one patient received needle 
insertion based on virtual preplanning with estimated needle 
position and depth of insertion from week 5 MRI. Estimated 
HRCTV D90wk5 tumor radius from midline was 3.6cm. 
Improvement of HRCTV D90wk5 from 4.9Gy and 8.33 Gy was 
noted before and after virtual needle insertion. The 
subsequent week 6 and 7 brachytherapy using the 
preplanning information showed excellent correlation in 
terms of HRCTV D90 dosimetry, with cumulative HRCTVactual 
89.2Gy (dose per fraction was 7.8, 7.5, 8.6 and 8.6Gy 
respectively). 
 
Conclusion: This study demonstrates the effectiveness of a 
non-invasive method using week 5 MRI for virtual pre-
planning, with accurate estimation of HRCTV, that can guide 
needle insertion diligently. Tumor radius of 2.5cm was 
proven to be a good reference to select patients for 
interstitial needle insertion. 
 
 
 
 
